A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Exendin 9 (Primary)
- Indications Hypoglycaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms PREVENT
- Sponsors Eiger BioPharmaceuticals, Inc.
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.
- 31 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2017.
- 16 Jan 2018 According to an Eiger BioPharmaceuticals media release, results from this trial are expected in the second half of 2018.